학술논문
Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
Document Type
Article
Author
Source
In Clinical Breast Cancer June 2016 16(3):180-187
Subject
Language
ISSN
1526-8209